These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 18223236

  • 1. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.
    Newman SP, Foster PA, Stengel C, Day JM, Ho YT, Judde JG, Lassalle M, Prevost G, Leese MP, Potter BV, Reed MJ, Purohit A.
    Clin Cancer Res; 2008 Jan 15; 14(2):597-606. PubMed ID: 18223236
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM.
    Cancer Chemother Pharmacol; 2008 Nov 15; 62(6):1045-54. PubMed ID: 18301895
    [Abstract] [Full Text] [Related]

  • 3. A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140.
    Foster PA, Stengel C, Ali T, Leese MP, Potter BV, Reed MJ, Purohit A, Newman SP.
    Anticancer Res; 2008 Nov 15; 28(3A):1483-91. PubMed ID: 18630502
    [Abstract] [Full Text] [Related]

  • 4. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
    Jin J, Wang FP, Wei H, Liu G.
    Cancer Chemother Pharmacol; 2005 Feb 15; 55(2):179-88. PubMed ID: 15378274
    [Abstract] [Full Text] [Related]

  • 5. A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer.
    Foster PA, Newman SP, Leese MP, Bernetiere S, Diolez C, Camara J, Hacher B, Baronnet MM, Ali T, Potter BV, Reed MJ, Purohit A.
    Anticancer Res; 2008 Feb 15; 28(2A):577-81. PubMed ID: 18506995
    [Abstract] [Full Text] [Related]

  • 6. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, Wiebesiek A, Vite G, Fairchild CR, Kramer R.
    Cancer Chemother Pharmacol; 2009 Jan 15; 63(2):201-12. PubMed ID: 18350296
    [Abstract] [Full Text] [Related]

  • 7. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 15; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 8. 2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer.
    Tagg SL, Foster PA, Leese MP, Potter BV, Reed MJ, Purohit A, Newman SP.
    Br J Cancer; 2008 Dec 02; 99(11):1842-8. PubMed ID: 18985042
    [Abstract] [Full Text] [Related]

  • 9. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.
    Hofstetter B, Vuong V, Broggini-Tenzer A, Bodis S, Ciernik IF, Fabbro D, Wartmann M, Folkers G, Pruschy M.
    Clin Cancer Res; 2005 Feb 15; 11(4):1588-96. PubMed ID: 15746064
    [Abstract] [Full Text] [Related]

  • 10. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
    Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA.
    Clin Cancer Res; 2001 May 15; 7(5):1429-37. PubMed ID: 11350914
    [Abstract] [Full Text] [Related]

  • 11. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H, Genne P, Kadhim S, Bibeau L, Duchamp O, Ouellet F, deMuys JM, Bouffard DY, Attardo G.
    Cancer Chemother Pharmacol; 2002 Dec 15; 50(6):490-6. PubMed ID: 12451476
    [Abstract] [Full Text] [Related]

  • 12. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
    Chou TC, Guan Y, Soenen DR, Danishefsky SJ, Boger DL.
    Cancer Chemother Pharmacol; 2005 Oct 15; 56(4):379-90. PubMed ID: 15875185
    [Abstract] [Full Text] [Related]

  • 13. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D, Greenberger LM, Beyer C, Hari M, Liu H, Baxter M, Yang S, Rios C, Discafani C.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [Abstract] [Full Text] [Related]

  • 14. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
    Park SJ, Wu CH, Safa AR.
    Anticancer Res; 2004 Jun 01; 24(1):123-31. PubMed ID: 15015586
    [Abstract] [Full Text] [Related]

  • 15. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K, Lamphere L, Unteregger G, Jung V, Kaplan F, Xu JP, Rattel B, Caligiuri M.
    Cancer Chemother Pharmacol; 2007 Sep 01; 60(4):589-600. PubMed ID: 17541592
    [Abstract] [Full Text] [Related]

  • 16. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK, Chiu P, Chung SS, Chow LM, Zhao YZ, Yang BB, Ko BC.
    Clin Cancer Res; 2005 Aug 15; 11(16):6002-11. PubMed ID: 16115945
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
    Zhu X, Sui M, Fan W.
    Anticancer Res; 2005 Aug 15; 25(3B):1953-62. PubMed ID: 16158930
    [Abstract] [Full Text] [Related]

  • 18. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
    Loganzo F, Discafani CM, Annable T, Beyer C, Musto S, Hari M, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, Poruchynsky MS, Fojo T, Nieman JA, Ayral-Kaloustian S, Zask A, Andersen RJ, Greenberger LM.
    Cancer Res; 2003 Apr 15; 63(8):1838-45. PubMed ID: 12702571
    [Abstract] [Full Text] [Related]

  • 19. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells.
    Dong K, Wang R, Wang X, Lin F, Shen JJ, Gao P, Zhang HZ.
    Breast Cancer Res Treat; 2009 Feb 15; 113(3):443-56. PubMed ID: 18327707
    [Abstract] [Full Text] [Related]

  • 20. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
    Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, Patel V, Kendall R, Radinsky R, Polverino A.
    Clin Cancer Res; 2009 Jan 01; 15(1):110-8. PubMed ID: 19118038
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.